ESTRO 2023 - Abstract Book

S531

Sunday 14 May 2023

ESTRO 2023

Conclusion This is the largest real-world evaluation of dose to the heart in a BC patient cohort. Most patients had a low MHD (<4Gy) in agreement with DBCG guidelines. Gated patients had lower MHD compared to non-gated patients. For gated patients (left sided), no significant difference in heart dose was found between using whole heart only or LADCA only as avoidance structure, validating the flexible choice of planning structure in DBCG guidelines. Differences for non-gated patients were likely related to difficulties meeting planning objectives. MO-0640 Structural cardiac changes in cardiac MRI after SBRT for targets in close proximity to the heart M. Ahmadsei 1 , B. Pouymayou 1 , S. Ehrbar 1 , J. von Spiczak 2 , S.M. Christ 1 , J. Willmann 1 , B. Kovacs 3 , R. Manka 4 , A.M. Saguner 3 , M. Guckenberger 1 , N. Andratschke 1 , M. Mayinger 1 1 University Hospital Zurich, Department of Radiation Oncology, Zurich, Switzerland; 2 University Hospital Zurich, Diagnostic and Interventional Radiology, Zurich, Switzerland; 3 University Hospital Zurich, Department of Cardiology, Zurich, Switzerland; 4 University Hospital Zurich, Diagnostic and Interventional Radiology and Department of Cardiology, Zurich, Switzerland Purpose or Objective Stereotactic body radiation therapy (SBRT) has become a standard of care for early stage non-small cell lung cancer and pulmonary oligometastases. Recent studies indicate that incidental irradiation of the heart is associated with a risk of increased non-cancer deaths. This study aims to assess and examine structural cardiac changes following peri- and epicardial SBRT using a systematic cardiac follow-up protocol including cardiac magnetic resonance (CMR) imaging. Materials and Methods For 1485 patients treated with local-ablative SBRT from January 2014 to February 2022 at our institution, the distance between the planning target volume (PTV) and the heart was measured. Forty-eight out of 134 patients treated in close proximity (<2cm) to the heart were alive at follow-up. Of those, 20 were randomly invited to undergo a structured cardiac follow-up protocol including CMR, transthoracic echocardiography (TTE), ECG, blood sampling, and two questionnaires, evaluating the quality of life and cardiac symptoms after SBRT, respectively. Ten patients agreed to participate. Registration of CMR image data and the SBRT treatment plan was performed to examine a possible correlation between the dose delivered to the myocardium and structural cardiac changes assessed by CMR. Automated segmentation of 17 heart sub-structures (great vessels, atria, ventricles, coronary arteries, valves, sinoatrial and atrioventricular nodes) was performed for detailed anatomical analysis. Results Among the 10 participating patients, the most common primary tumors were non-small cell lung cancer (n=3) and small cell lung cancer (n=2) (Table 1). Five patients presented with pre-SBRT cardiovascular comorbidities including coronary artery disease and atrial fibrillation. Seven patients received SBRT for pulmonary or vertebral metastases and three patients for primary lung cancer with a median dose of 42.5 Gy (30.0-48.0 Gy) in 3-10 fractions. The mean heart dose (Dmean) and maximum heart dose (Dmax) were 4.9 Gy (0.7-8.4 Gy) and 36.2 Gy (8.3 – 64.1 Gy), respectively. On CMR, five patients showed myocardial alterations, such as fibrosis and edema after a median follow-up time of 5.6 years (0.1-6.3 years). All detected lesions were overlapping or in close proximity to the PTV within the myocardium (Figure 1). Patients with structural changes of the myocardium showed significantly higher Dmax (135.4 Gy vs. 25.4 Gy, p=0.009), Dmean (4.4 Gy vs. 3.4 Gy, p=0.05), D0.1cc (106.3 Gy vs. 21.5 Gy, p=0.006) and D0.03 (117.2 Gy vs. 22.9 Gy, p=0.007). Structural changes on CMR showed a Dmean of 25.9 Gy (21.7-38.3 Gy; EQD2 α / β =3 Gy: 49.4 Gy, 24.8-64.9 Gy) and a Dmax of 40.5 Gy (29.1-61.8 Gy; EQD2 α / β =3 Gy: 110.65 Gy, 38.6-146.2 Gy).